FDA-approved GHRH analog with strong evidence for visceral fat reduction.
Tesamorelin is an FDA-approved GHRH analog studied extensively for reduction of visceral adipose tissue (VAT). It has become popular in longevity practice for patients with metabolic-syndrome features.
Nightly subcutaneous injection; effects on visceral fat typically measurable at 12–26 weeks.
GHRH-receptor agonist increasing endogenous GH and IGF-1, with disproportionate lipolytic effect on VAT.
Not indicated in active malignancy. Monitor glucose and IGF-1.
This page is educational and not medical advice. All VitaFlow protocols require evaluation by a licensed Florida physician.
Tesamorelin has strong FDA evidence specifically for visceral fat.
12–26 weeks with lifestyle support.
Only under physician supervision.
IGF-1, fasting glucose, HbA1c.
GHRH analog that stimulates your body's own growth hormone in a physiologic pattern.
Long-acting GHRH analog often paired with Ipamorelin for GH optimization.
Selective GH secretagogue with minimal impact on cortisol, prolactin or appetite.
Meet with a VitaFlow physician to design a protocol tailored to your goals, biomarkers, and lifestyle.
